Picture of Essex Bio-Technology logo

1061 — Essex Bio-Technology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Hong Kong's Essex Bio-Technology H1 revenue falls

Hong Kong's Essex Bio-Technology H1 revenue falls


Overview

  • Hong Kong biopharma firm's H1 turnover fell 10.5% yr/yr to HK$784.7 mln

  • Net profit for H1 dropped 32.2% yr/yr, with EPS at HK19.53 cents

  • Company cut interim dividend to HK5.0 cents from HK7.0 cents last year


Outlook

  • Company did not provide specific financial guidance or outlook for future periods


Result Drivers

  • HIGHER EXPENSES - Administrative costs, rose yr/yr and contributed to lower profitability

  • MARGIN DECLINE - Gross profit margin and net profit margin fell compared to prior yr


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Revenue

HK$784.69 mln


Analyst Coverage

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Aug 3 - China's WuXi AppTec H1 revenue rises, raises 2026 guidance

  • Aug 4 - Pfizer Q2 results beat; raises 2026 revenue outlook

  • Aug 4 - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Essex Bio-Technology

See all news